{"entity":{"id":"nct04454437","kind":"trial","name":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","aka":[],"tldr":"A phase 2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments is a phase 2 interventional study registered as NCT04454437 by Gilead Sciences, with 80 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2021-08-06. Interventions recorded: Sacituzumab Govitecan-hziy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04454437","url":"https://clinicaltrials.gov/study/NCT04454437"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-metastatic"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04454437-int-j-cancer-2023"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04454437","phase":"2","setting":"A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","sponsor":"Gilead Sciences","started":"2020-10-23","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04454437/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"paper":[{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/"}]}}